These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20507183)

  • 1. Prevalidation of the rat CFU-GM assay for in vitro toxicology applications.
    Pessina A; Bonomi A; Cavicchini L; Albella B; Cerrato L; Parent-Massin D; Sibiril Y; Parchment R; Behrsing H; Verderio P; Pizzamiglio S; Giangreco M; Baglio C; Coccè V; Sisto F; Gribaldo L
    Altern Lab Anim; 2010 May; 38(2):105-17. PubMed ID: 20507183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refinement and optimisation of the rat CFU-GM assay to incorporate the use of cryopreserved bone-marrow cells for in vitro toxicology applications.
    Pessina A; Bonomi A; Baglio C; Cavicchini L; Gribaldo L
    Altern Lab Anim; 2009 Sep; 37(4):417-25. PubMed ID: 19807213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A methylcellulose microculture assay for the in vitro assessment of drug toxicity on granulocyte/macrophage progenitors (CFU-GM).
    Pessina A; Croera C; Bayo M; Malerba I; Passardi L; Cavicchini L; Neri MG; Gribaldo L
    Altern Lab Anim; 2004 Mar; 32(1):17-23. PubMed ID: 15603550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation.
    Moneta D; Geroni C; Valota O; Grossi P; de Jonge MJ; Brughera M; Colajori E; Ghielmini M; Sessa C
    Eur J Cancer; 2003 Mar; 39(5):675-83. PubMed ID: 12628848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay.
    Pessina A; Albella B; Bueren J; Brantom P; Casati S; Gribaldo L; Croera C; Gagliardi G; Foti P; Parchment R; Parent-Massin D; Sibiril Y; Van Den Heuvel R
    Toxicol In Vitro; 2001 Dec; 15(6):729-40. PubMed ID: 11698175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro tests for haematotoxicity: prediction of drug-induced myelosuppression by the CFU-GM assay.
    Pessina A; Albella B; Bayo M; Bueren J; Brantom P; Casati S; Croera C; Parchment R; Parent-Massin D; Schoeters G; Sibiri Y; Van Den Heuvel R; Gribaldo L
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():75-9. PubMed ID: 12513654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743).
    Gómez SG; Bueren JA; Faircloth G; Albella B
    Toxicol In Vitro; 2003; 17(5-6):671-4. PubMed ID: 14599461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.
    Pessina A; Albella B; Bayo M; Bueren J; Brantom P; Casati S; Croera C; Gagliardi G; Foti P; Parchment R; Parent-Massin D; Schoeters G; Sibiril Y; Van Den Heuvel R; Gribaldo L
    Toxicol Sci; 2003 Oct; 75(2):355-67. PubMed ID: 12883091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro sensitivity of granulo-monocytic progenitors as a new toxicological cell system and endpoint in the ACuteTox Project.
    Cerrato L; Valeri A; Bueren JA; Albella B
    Toxicol Appl Pharmacol; 2009 Jul; 238(2):111-9. PubMed ID: 19442680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs.
    Pessina A; Parent-Massin D; Albella B; Van Den Heuvel R; Casati S; Croera C; Malerba I; Sibiril Y; Gomez S; de Smedt A; Gribaldo L
    Toxicol In Vitro; 2009 Feb; 23(1):194-200. PubMed ID: 19084588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refinement of the colony-forming unit-megakaryocyte (CFU-MK) assay for its application to pharmaco-toxicological testing.
    Casati S; Collotta A; Clothier R; Gribaldo L
    Toxicol In Vitro; 2003 Feb; 17(1):69-75. PubMed ID: 12537964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new experimental protocol as an alternative to the colony-forming unit-granulocyte/macrophage (CFU-GM) clonogenic assay to assess the haematotoxic potential of new drugs.
    Dal Negro G; Vandin L; Bonato M; Repeto P; Sciuscio D
    Toxicol In Vitro; 2006 Aug; 20(5):750-6. PubMed ID: 16321498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of drug-induced hematotoxicity using novel in vitro monkey CFU-GM and BFU-E colony assays.
    Goto K; Goto M; Ando-Imaoka M; Kai K; Mori K
    J Toxicol Sci; 2017; 42(4):397-405. PubMed ID: 28717098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.
    Masubuchi N; May RD; Atsumi R
    Clin Cancer Res; 2004 Oct; 10(19):6722-31. PubMed ID: 15475463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.
    Song H; Vita M; Sallam H; Tehranchi R; Nilsson C; Sidén A; Hassan Z
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):841-9. PubMed ID: 17318617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials.
    Pessina A; Malerba I; Gribaldo L
    Curr Pharm Des; 2005; 11(8):1055-65. PubMed ID: 15777255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CFU-GM assay for evaluation of drug myelotoxic activity.
    Pessina A; Bonomi A
    Curr Protoc Toxicol; 2007 Nov; Chapter 20():Unit20.2. PubMed ID: 23045143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification of rat megakaryocyte colony-forming cells using a monoclonal antibody against rat platelet glycoprotein IIb/IIIa.
    Miyazaki H; Inoue H; Yanagida M; Horie K; Mikayama T; Ohashi H; Nishikawa M; Suzuki T; Sudo T
    Exp Hematol; 1992 Aug; 20(7):855-61. PubMed ID: 1628703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.